Skip to Main content
Skip to Navigation
Toggle navigation
HAL
HAL
HALSHS
TEL
MédiHAL
Liste des portails
AURéHAL
API
Data
Documentation
Episciences.org
Episciences.org
Journals
Documentation
Sciencesconf.org
Support
Sign in
Sign in
Sign in with ORCID
se connecter avec Fédération
Create account
Forgot your password?
Have you forgotten your login?
fr
en
Centre François Baclesse
Home
Home
Collection HAL FNCLCC
Browse
All documents
By year
By authors in the Centre
By document type
Simple search
Centre site
Home
Home
Last submissions
Marion Dhooge, Stéphanie Baert-Desurmont, Carole Corsini, Olivier Caron, Nadine Andrieu, et al.. National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract. European Journal of Medical Genetics, Elsevier, 2020, 63 (12), pp.104080. ⟨10.1016/j.ejmg.2020.104080⟩. ⟨inserm-03182974⟩
François Chevalier, Dounia Houria Hamdi, Charlotte Lepleux, Mihaela Temelie, Anaïs Nicol, et al.. High LET Radiation Overcomes In Vitro Resistance to X-Rays of Chondrosarcoma Cell Lines. Technology in Cancer Research and Treatment, Adenine Press, 2019, 18, pp.153303381987130. ⟨10.1177/1533033819871309⟩. ⟨hal-02333914⟩
Paul Lesueur, François Chevalier, Jean-Baptiste Austry, Waisse Waissi, Hélène Burckel, et al.. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget, Impact journals, 2017, 8 (40), ⟨10.18632/oncotarget.19079⟩. ⟨hal-02493848⟩
Dounia Houria Hamdi, Charlotte Lepleux, Agnès Nicolle, Guillaume Varès, Paul Lesueur, et al.. High LET Radiation Overcomes in vitro Resistance to X-rays of Chondrosarcoma Cell Lines. ENLIGHT Annual Meeting and Training 2019, Jul 2019, Caen, France. ⟨hal-03144579⟩
Guillaume Vogin, Liza Hettal, Clarisse Bartau, Juliette Thariat, Marie-Virginie Claeys, et al.. Cranial organs at risk delineation: heterogenous practices in radiotherapy planning. Radiation Oncology, BioMed Central, 2021, 16, pp.26. ⟨10.1186/s13014-021-01756-y⟩. ⟨hal-03134498⟩
Steven Le Gouill, Hervé Ghesquieres, Lucie Obéric, Franck Morschhauser, Herve Tilly, et al.. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, ⟨10.1182/blood.2020008750⟩. ⟨hal-03122586⟩
Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, et al.. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. BMC Cancer, BioMed Central, 2020, 20 (1), pp.352. ⟨10.1186/s12885-020-06841-1⟩. ⟨hal-03130294⟩
Astrid Lièvre, Anthony Turpin, Isabelle Ray-Coquard, Karine Le Malicot, Juliette Thariat, et al.. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).. European Journal of Cancer, Elsevier, 2020, 141, pp.62-81. ⟨10.1016/j.ejca.2020.09.035⟩. ⟨hal-02998283⟩
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, et al.. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiotherapy and Oncology, Elsevier, 2020, 154 (227-234), ⟨10.1016/j.radonc.2020.09.036⟩. ⟨hal-02954534⟩
Christian Pfister, Valentin Harter, Yves Allory, François Radvanyi, Stéphane Culine, et al.. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemporary Clinical Trials Communications, Elsevier, 2020, 17, pp.100536. ⟨10.1016/j.conctc.2020.100536⟩. ⟨hal-02909542⟩
Number of fulltext
53
Number of reference
Submissions evolution
Submissions distribution by document type